IL150987A0 - Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization - Google Patents

Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

Info

Publication number
IL150987A0
IL150987A0 IL15098700A IL15098700A IL150987A0 IL 150987 A0 IL150987 A0 IL 150987A0 IL 15098700 A IL15098700 A IL 15098700A IL 15098700 A IL15098700 A IL 15098700A IL 150987 A0 IL150987 A0 IL 150987A0
Authority
IL
Israel
Prior art keywords
polypeptides
present
cardiovascularization
angiogenesis
modulation
Prior art date
Application number
IL15098700A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/en
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL150987A0 publication Critical patent/IL150987A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
IL15098700A 2000-02-11 2000-12-19 Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization IL150987A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2000/003565 WO2001053486A1 (en) 1999-03-08 2000-02-11 Compositions and methods for the treatment of tumor
PCT/US2000/006884 WO2001005972A1 (en) 1999-07-20 2000-03-15 Compositions and methods for the treatment of immune related diseases
US25366500P 2000-11-28 2000-11-28
PCT/US2000/034756 WO2001059100A2 (en) 2000-02-11 2000-12-19 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
IL150987A0 true IL150987A0 (en) 2003-02-12

Family

ID=39048807

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15098700A IL150987A0 (en) 2000-02-11 2000-12-19 Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
IL150987A IL150987A (en) 2000-02-11 2002-07-30 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150987A IL150987A (en) 2000-02-11 2002-07-30 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

Country Status (13)

Country Link
US (2) US6800604B2 (xx)
EP (1) EP1255829B1 (xx)
JP (2) JP2003527844A (xx)
AT (1) ATE440139T1 (xx)
AU (1) AU3075701A (xx)
CA (1) CA2398775A1 (xx)
CY (1) CY1109518T1 (xx)
DE (1) DE60042793D1 (xx)
DK (1) DK1255829T3 (xx)
ES (1) ES2330918T3 (xx)
IL (2) IL150987A0 (xx)
PT (1) PT1255829E (xx)
WO (1) WO2001059100A2 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589172B2 (en) * 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
EP1585484A4 (en) * 2002-10-07 2008-04-16 Genentech Inc VARIANTS OF HEPATOCYTE GROWTH FACTOR
WO2004104215A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
RS53476B (en) 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
US20080305106A1 (en) * 2004-05-12 2008-12-11 Jane Brennan Novel Gene Disruptions, Composition and Methods Relating Thereto
EP1812071A2 (en) 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
EP2205249B1 (en) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
US20130149788A1 (en) * 2011-12-09 2013-06-13 Cornell University Assay for quantifying elemental sulfur levels in a sample
US10743996B2 (en) * 2017-03-24 2020-08-18 Robert L. Bundy Amnion putty for cartilage repair

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
DE69434566T2 (de) 1993-04-05 2006-07-13 University Of Utah Research Foundation, Salt Lake City Diagnose und behandlung von supravalvular aortic stenosis
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5661122A (en) 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
WO1995029237A1 (en) 1994-04-25 1995-11-02 Genentech, Inc. Cardiotrophin and uses therefor
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
EP0759467B1 (en) 1995-07-24 2004-02-11 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
WO1997012629A1 (en) 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
JPH1135480A (ja) * 1997-07-15 1999-02-09 Mitsubishi Chem Corp プロテアーゼの活性亢進に起因する疾患の予防及び／または治療剤
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.

Also Published As

Publication number Publication date
DE60042793D1 (de) 2009-10-01
IL150987A (en) 2009-09-01
JP2012246296A (ja) 2012-12-13
CA2398775A1 (en) 2001-08-16
JP2003527844A (ja) 2003-09-24
AU3075701A (en) 2001-08-20
EP1255829A2 (en) 2002-11-13
ES2330918T3 (es) 2009-12-17
EP1255829B1 (en) 2009-08-19
PT1255829E (pt) 2009-11-26
US20040132660A1 (en) 2004-07-08
ATE440139T1 (de) 2009-09-15
US6800604B2 (en) 2004-10-05
US20020123091A1 (en) 2002-09-05
WO2001059100A2 (en) 2001-08-16
CY1109518T1 (el) 2014-08-13
DK1255829T3 (da) 2009-12-14
WO2001059100A3 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
IL202176A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053757A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DK1032668T3 (da) Fibroblast vækstfaktor 19
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
EP1669371A3 (en) Composition and methods for the diagnosis of tumours
DE69940964D1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
WO2002000711A3 (en) Ev-vegf nucleic acids and polypeptides and methods of use
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2001025433A3 (en) Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
WO2000066156A8 (en) Death domain containing receptor 5
PT1212417E (pt) Promoção ou inibição de angiogénese e cardiovascularização
WO2001040464A8 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1734051A3 (en) Composition and methods for the diagnosis of tumours
ATE295874T1 (de) Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung.